samedan logo
 
 
 
spacer
home > ebr > summer 2004 > european life sciences
PUBLICATIONS
European Biopharmaceutical Review

European Life Sciences

As the biotech sector continues to mature, its leading companies will deliver more and more products thereby dramatically improving overall sentiment towards the sector. Despite the investor challenges experienced in recent years, over the past 12-18 months we have witnessed a significant and sustained upswing in the US and European markets, as well as in the biotechnology sector in general. On the whole, the prices of quoted companies in both the US and Europe significantly improved over the year to December 2003, with the NASDAQ Biotech Index up more than 50 per cent over the previous 12 months (1). However, since March 2004 there has been a slight correction in both US and European biotech stocks (as shown in Figure 1).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Mark Clement, Chief Executive of Merlin Biosciences

Mark Clement is Chief Executive Officer at Merlin Biosciences. He joined Merlin in March 2000 and serves as Chief Executive. In 1997, he founded MCC Services, a corporate finance consultancy, where he led assignments from nine life sciences companies, including four Fund I investments. In 1992, he co-founded Celsis International plc (a specialist in microbial risk management), where he served as Group Finance Director with responsibility for both finance and European operations. Prior to this, he spent a year at WestLB Panmure as an Associate Director (Corporate Finance). Mark is a Fellow of the Institutes of Chartered Accountants in England and Wales, the Securities Institute and the Insolvency Practitioners Association.

spacer
Mark Clement
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Advanced Clinical Continues Global Expansion Into Asia-Pacific With New Office in Australia

Advanced Clinical, a global clinical research services organization, continues to build upon its growth strategy in the Asia-Pacific (APAC) region with the opening of a new office in Sydney, Australia.
More info >>

White Papers

Migration safe pharmaceutical labels improve patient safety

UPM Raflatac

Labels play an invaluable role on pharmaceutical packages. Pharmaceutical companies should only use labels that meet low-leachability and extraction requirements. Labels that are not migration safe, e.g. create leachable chemical compounds, may fail testing and result in significant launch delays or costly recalls. This white paper presents how pharmaceutical companies can ensure that the final label constructions achieve their business, regulatory and patient safety goals.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement